Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148317 | 1.00 | TSHR (0.41) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10148231 | 0.90 | ALDH1A1 (0.42) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10148319 | 0.90 | ALDH1A1 (0.42) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10184863 | 0.83 | TSHR (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10185041 | 0.83 | TSHR (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10186391 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4441490 | 0.82 | TSHR (0.54) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10148349 | 0.81 | ALDH1A1 (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL661513 | 0.81 | ALDH1A1 (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL661512 | 0.81 | ALDH1A1 (0.43) | TSHRALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | TSHR 4189/4885ALDH1A1 963/4885KDM4E 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.